Inhibrx Net Income vs. Shares Outstanding

INBX Stock  USD 15.63  0.18  1.17%   
Based on the key profitability measurements obtained from Inhibrx's financial statements, Inhibrx may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Inhibrx's ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2018-03-31
Previous Quarter
1.9 B
Current Value
-43.9 M
Quarterly Volatility
378.4 M
 
Covid
At this time, Inhibrx's Price To Sales Ratio is fairly stable compared to the past year. Days Sales Outstanding is likely to rise to 165.65 in 2024, despite the fact that Operating Cash Flow Sales Ratio is likely to grow to (102.02). Inhibrx reported Accumulated Other Comprehensive Income of (150.45 Million) in 2023. Change To Netincome is likely to rise to about 24.7 M in 2024, despite the fact that Net Loss is likely to grow to (124.2 M).
For Inhibrx profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Inhibrx to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Inhibrx utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Inhibrx's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Inhibrx over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibrx. If investors know Inhibrx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibrx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
119.39
Revenue Per Share
0.117
Quarterly Revenue Growth
2.333
Return On Assets
(0.57)
Return On Equity
(20.31)
The market value of Inhibrx is measured differently than its book value, which is the value of Inhibrx that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibrx's value that differs from its market value or its book value, called intrinsic value, which is Inhibrx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibrx's market value can be influenced by many factors that don't directly affect Inhibrx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibrx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inhibrx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibrx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Inhibrx Shares Outstanding vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Inhibrx's current stock value. Our valuation model uses many indicators to compare Inhibrx value to that of its competitors to determine the firm's financial worth.
Inhibrx is rated below average in net income category among its peers. It also is rated below average in shares outstanding category among its peers . Inhibrx reported Net Loss of (241.36 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inhibrx's earnings, one of the primary drivers of an investment's value.

Inhibrx Shares Outstanding vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Inhibrx

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(241.36 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Inhibrx

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
14.48 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.

Inhibrx Shares Outstanding Comparison

Inhibrx is currently under evaluation in shares outstanding category among its peers.

Inhibrx Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Inhibrx, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Inhibrx will eventually generate negative long term returns. The profitability progress is the general direction of Inhibrx's change in net profit over the period of time. It can combine multiple indicators of Inhibrx, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Net Loss-130.7 M-124.2 M
Net Interest Income-19.9 M-18.9 M
Operating Income-219.2 M-208.3 M
Net Loss-188.7 M-179.2 M
Income Before Tax-239.7 M-227.7 M
Total Other Income Expense Net-20.5 M-19.5 M
Net Loss-241.4 M-229.3 M
Income Tax Expense2.7 K2.6 K
Non Operating Income Net Other 900.00  855.00 
Interest Income11.9 M7.7 M
Change To Netincome23.5 M24.7 M
Net Loss(5.12)(4.87)
Income Quality 0.80  1.05 
Net Income Per E B T 1.01  0.76 

Inhibrx Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Inhibrx. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Inhibrx position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Inhibrx's important profitability drivers and their relationship over time.

Use Inhibrx in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inhibrx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibrx will appreciate offsetting losses from the drop in the long position's value.

Inhibrx Pair Trading

Inhibrx Pair Trading Analysis

The ability to find closely correlated positions to Inhibrx could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inhibrx when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inhibrx - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inhibrx to buy it.
The correlation of Inhibrx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inhibrx moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inhibrx moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Inhibrx can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Inhibrx position

In addition to having Inhibrx in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Fabricated Products Thematic Idea Now

Fabricated Products
Fabricated Products Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Fabricated Products theme has 11 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Fabricated Products Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.